PMV PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.66 USD | -1.19% |
|
+3.11% | -46.45% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,754 | 1,048 | 397.3 | 158.6 | 85.4 | - | - |
| Enterprise Value (EV) 1 | 2,393 | 751.1 | 289 | 120.9 | 51.64 | 59.93 | -36.05 |
| P/E ratio | -25.6 x | -18 x | -5.4 x | -2.15 x | -1.23 x | -1.11 x | -1.2 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 36.5 x |
| EV / Revenue | - | - | - | - | - | - | -15.4 x |
| EV / EBITDA | -69.1 x | -13 x | -3.77 x | -1.53 x | -0.63 x | -0.6 x | 0.31 x |
| EV / FCF | -72.8 x | - | - | - | -0.72 x | -0.82 x | 0.43 x |
| FCF Yield | -1.37% | - | - | - | -138% | -123% | 233% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 44,774 | 45,380 | 45,665 | 51,158 | 51,443 | - | - |
| Reference price 2 | 61.51 | 23.10 | 8.700 | 3.100 | 1.660 | 1.660 | 1.660 |
| Announcement Date | 03/03/21 | 01/03/22 | 01/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 2.34 |
| EBITDA 1 | - | -34.62 | -57.99 | -76.72 | -78.88 | -82.4 | -100.7 | -115.4 |
| EBIT 1 | - | -34.94 | -58.29 | -77.04 | -80.13 | -79.02 | -87.92 | -95.35 |
| Operating Margin | - | - | - | - | - | - | - | -4,074.65% |
| Earnings before Tax (EBT) 1 | - | -34.43 | -57.82 | -73.33 | -68.96 | -72.08 | -82.15 | -87.45 |
| Net income 1 | -25.35 | -34.44 | -57.85 | -73.32 | -68.96 | -72.16 | -82.15 | -87.45 |
| Net margin | - | - | - | - | - | - | - | -3,737.35% |
| EPS 2 | -8.372 | -2.400 | -1.280 | -1.610 | -1.440 | -1.350 | -1.497 | -1.387 |
| Free Cash Flow 1 | - | -32.89 | - | - | - | -71.5 | -73.5 | -84 |
| FCF margin | - | - | - | - | - | - | - | -3,589.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 26/06/20 | 03/03/21 | 01/03/22 | 01/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -18.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.47 | -18.62 | -17.88 | -19.38 | -21.16 | -21.48 | -20.12 | -19.63 | -18.9 | -18.22 | -19.67 | -20.12 | -21.07 | -22.54 | -22.78 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.36 | -18.43 | -17.31 | -18.24 | -19.34 | -19.13 | -17.43 | -16.64 | -15.76 | -15.27 | -17.56 | -18.04 | -19.16 | -20.95 | -21.63 |
| Net income 1 | -18.36 | -18.43 | -17.31 | -18.23 | -19.34 | -19.13 | -17.44 | -16.64 | -15.76 | -15.27 | -17.56 | -18.04 | -19.16 | -20.95 | -21.63 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4000 | -0.4100 | -0.3800 | -0.4000 | -0.4300 | -0.4200 | -0.3800 | -0.3400 | -0.3100 | -0.3000 | -0.3333 | -0.3450 | -0.3650 | -0.4067 | -0.4200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 01/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 01/03/23 | 10/05/23 | 09/08/23 | 09/11/23 | 29/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 361 | 297 | 108 | 37.7 | 33.8 | 25.5 | 121 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -32.9 | - | - | - | -71.5 | -73.5 | -84 |
| ROE (net income / shareholders' equity) | - | -15.1% | -17.3% | -26.4% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | -2.280 | -1.030 | -1.400 | - | - | - | - |
| Capex | - | 0.15 | - | - | 0.96 | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 26/06/20 | 03/03/21 | 01/03/22 | 01/03/23 | 29/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.66
USD
Average target price
5.75
USD
Spread / Average Target
+246.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.45% | 85.4M | |
| +23.13% | 46.93B | |
| +37.49% | 39.08B | |
| -8.73% | 38.48B | |
| +28.09% | 31.01B | |
| -12.26% | 26.14B | |
| +10.57% | 25.88B | |
| +45.05% | 14.15B | |
| +32.23% | 12.53B | |
| -6.56% | 11.36B |
- Stock Market
- Equities
- PMVP Stock
- Financials PMV Pharmaceuticals, Inc.
